Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease

Hepatology

Volumn 35, Issue 6, 2002, Pages 1528-1535

  Steinmüller, Thomas ^a   Seehofer, Daniel ^a   Rayes, Nada ^a   Müller, Andrea R ^a   Settmacher, Utz ^a   Jonas, Sven ^a   Neuhaus, Ruth ^a   Berg, Thomas ^a   Hopf, Uwe ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; LAMIVUDINE;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA HYBRIDIZATION; FEMALE; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REINFECTION; SUPERINFECTION; SURVIVAL RATE; TREATMENT INDICATION; VIRUS REPLICATION;

EID: 3042828511     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.33681     Document Type: Article

References (45)

1. Liver transplantation in European patients with the hepatitis B surface antigen
2. Long-term follow up of hepatitis B virus-infected recipients after orthotopic liver transplantation
3. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
4. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients
5. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization
6. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
7. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
8. Long term outcome of liver transplantation for viral hepatitis: Is there need to re-evaluate patient selection?
9. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis
10. Liver transplantation for hepatitis B: The con aspect
11. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study
12. Long term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation
13. Efficacy oflamivudine in controlling hepatitis B virus recurrence after liver transplantation
14. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
15. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
16. Lamivudine as first and second line treatment of hepatitis B infection after liver transplantation
17. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: A preliminary report
18. Chronic hepatitis B
19. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis
20. Liver transplantation and HBsAg positive postnecrotic cirrhosis: Adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis
21. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis
22. Hepatitis B and C coinfections and persistent hepatitis B infections: Clinical outcome and liver pathology after transplantation
23. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression
24. Recurrence free long-term survival after liver transplantation for hepatitis B using interferon-alphy pretransplant and hepatitis B immune globulin posttransplant
25. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
26. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
27. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation
28. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
29. Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function
30. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
31. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis
32. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
33. Pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis
34. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation
35. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
36. Beneficial effect of lamivudine pre- and post-liver transplantation for hepatitis B infection
37. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
38. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
39. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
40. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
41. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
42. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
43. Occurrence and clinical outcome of lamivudine resistant hepatitis B infection after liver transplantation
44. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
45. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis